Vir Biotechnology (NASDAQ:VIR) EVP Sells $33,115.25 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 4,445 shares of the business’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $33,115.25. Following the completion of the transaction, the executive vice president directly owned 129,799 shares of the company’s stock, valued at approximately $967,002.55. This represents a 3.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Vir Biotechnology Price Performance

Shares of VIR stock traded up $2.06 during trading hours on Tuesday, reaching $9.49. 38,240,174 shares of the company were exchanged, compared to its average volume of 1,972,225. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.29. The stock’s fifty day moving average is $6.80 and its two-hundred day moving average is $5.99. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -3.00 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. The firm had revenue of $64.07 million for the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 47.14% and a negative net margin of 638.88%.The business’s revenue for the quarter was up 417.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.76) EPS. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Institutional Trading of Vir Biotechnology

Several hedge funds have recently added to or reduced their stakes in VIR. AQR Capital Management LLC lifted its holdings in Vir Biotechnology by 2,088.4% during the first quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after acquiring an additional 256,037 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Vir Biotechnology during the first quarter worth about $359,000. Goldman Sachs Group Inc. lifted its holdings in shares of Vir Biotechnology by 43.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares in the last quarter. Woodline Partners LP grew its position in shares of Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares during the period. Finally, Focus Partners Wealth grew its position in shares of Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares during the period. Institutional investors and hedge funds own 65.32% of the company’s stock.

Trending Headlines about Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas strategic collaboration: Vir announced a global co‑development/co‑commercialization collaboration with Astellas for prostate cancer candidate VIR‑5500 that includes $335M upfront/near‑term payments, up to $1.37B in additional milestones, a 50/50 U.S. profit/loss split, Astellas leading U.S. commercialization and ex‑U.S. rights, plus tiered double‑digit ex‑U.S. royalties — a major de‑risking and validation event for the program. Read More.
• Positive Sentiment: Encouraging Phase 1 VIR‑5500 data: Updated trial results show a favorable safety profile and meaningful activity (reported ORR ~45% at higher doses in later cohorts), supporting the value of the asset and underpinning the Astellas deal. Read More.
• Positive Sentiment: Quarterly beat and strong revenue growth: Q4 EPS of ($0.31) beat estimates and revenue of $64.1M significantly exceeded the consensus (~$19.9M), with revenue up ~418% year‑over‑year — evidence of commercial traction and stronger near‑term financial performance. Read More.
• Positive Sentiment: Analyst upgrade: Needham raised its price target to $18 and maintained a buy rating, adding institutional validation and support for higher upside expectations. Read More.
• Neutral Sentiment: Broad media coverage and analyst commentary: Multiple outlets (Forbes, Seeking Alpha, MSN) are highlighting the deal, data and earnings beat — amplifying attention and trading volume but not adding new fundamentals. Read More.
• Neutral Sentiment: Company disclosures and materials: Earnings call transcript and slide deck provide more color on pipeline prioritization (HDV, oncology) and capital deployment plans. Read More.
• Negative Sentiment: Proposed public offering: Vir filed to sell additional shares, which can be dilutive and weigh on near‑term share price despite the cash proceeds. Read More.
• Negative Sentiment: Ongoing losses and wide negative margins: The company reported a large 2025 net loss (and very negative margins), so long‑term value depends on successful development/commercial execution and milestone/cash management. Read More.

Analyst Ratings Changes

VIR has been the subject of a number of research reports. Evercore reiterated an “outperform” rating and issued a $18.00 price objective on shares of Vir Biotechnology in a research report on Tuesday. Barclays reiterated an “overweight” rating and set a $30.00 price target on shares of Vir Biotechnology in a research report on Tuesday. Needham & Company LLC increased their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Finally, Morgan Stanley upped their target price on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $19.88.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.